Blood Feud
In biotech, one drug can make a company. For Amgen of Thousand Oaks, Calif., the nation’s largest biotech firm, that drug is the anemia treatment erythropoietin (EPO). The best-selling protein racked up $2 billion in revenues for Amgen in 1999 and is paying for the 87,000-square-meter (285,000-square-foot), state-of-the-art laboratory the company is building in the heart of Cambridge, Mass.
But just a few blocks away, at Transkaryotic Therapies (TKT), some clever Cambridge competitors are set to challenge Amgen’s pre-eminence with a version of EPO they believe gets around Amgen’s suite of patents. If successful, TKT’s “end-around” could lead to additional knockoffs of some of the world’s largest-selling biotech pharmaceuticals.
In the early 1980s, Amgen was first to discover and patent the gene that encodes the EPO protein. To manufacture EPO, Amgen adds a copy of the gene to rodent cells growing in culture. TKT’s strategy calls for using human cells instead; latent copies of the EPO gene are turned on in human cells grown in the lab, bypassing Amgen’s patents on the gene and its production method.
Amgen originally hauled TKT into court in 1997. But TKT sidestepped the legal challenge thanks to a loophole that immunizes companies from patent infringement suits while testing a drug. Now that TKT and its partner, the French-based drug firm Aventis, have finished studies in patients and are preparing to seek FDA approval to market its version of EPO, the parties are set to meet Amgen in a Boston courtroom this April.
Robert Frank, an attorney with Boston’s Choate, Hall & Stewart who represents TKT, says the case will be significant not only because of the money at stake, but also because it will test just how well-defended the patents that undergird biotech’s pioneering companies really are. TKT is betting that it’s found a chink in their armor. After EPO, TKT has secrecy-shrouded plans to take on six more of the top drugs in the worldwide $15 billion protein-therapy market.
Keep Reading
Most Popular

The big new idea for making self-driving cars that can go anywhere
The mainstream approach to driverless cars is slow and difficult. These startups think going all-in on AI will get there faster.

Inside Charm Industrial’s big bet on corn stalks for carbon removal
The startup used plant matter and bio-oil to sequester thousands of tons of carbon. The question now is how reliable, scalable, and economical this approach will prove.

The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

The hype around DeepMind’s new AI model misses what’s actually cool about it
Some worry that the chatter about these tools is doing the whole field a disservice.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.